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Open access under CC BY license.Neutrophils play a key role in the elimination of patho-
gens. They are remarkably short-lived with a circulating
half life of 6–8 h and hence are produced at a rate of
5  1010–10  1010 cells/day. Tight regulation of these
cells is vital because they have significant histotoxic
capacity and are widely implicated in tissue injury. This
review outlines our current understanding of how neu-
trophils are released from the bone marrow; in particu-
lar, the role of the CXC chemokine receptor 4/stromal-
derived factor 1 axis, the relative size and role of the
freely circulating and marginated (i.e. slowly transiting)
pools within the vascular compartment, and the events
that result in the uptake and removal of circulating
neutrophils. We also review current understanding of
how systemic stress and inflammation affect this finely
balanced system.
Neutrophil homeostasis
Neutrophils are the most abundant circulating leukocyte
in humans and play a fundamental role in the innate
immune response. This is best exemplified by patients
with neutropenia, chronic granulomatous disease or leu-
kocyte adhesion deficiency syndrome, who are particularly
prone to bacterial and fungal infection. Neutrophils are
recruited rapidly to sites of inflammation, where their
primary role is to kill invading bacteria and certain fungal
species through phagocytosis by release of preformed gran-
ular enzymes and proteins, and by the production of a
range of oxygen species. However, the highly destructive
capacity of these cells also raises the potential for neutro-
phils to damage healthy tissues, which occurs in many
inflammatory diseases such as acute respiratory distress
syndrome, inflammatory bowel disease, and rheumatoid
arthritis. Neutrophil abundance, coupled with their brief
(6–8 h) circulating half life, mandates a basal rate of pro-
duction by the bone marrow of 5  1010–10  1010 neutro-
phils/day; the advantage to the host of this rapid turnover
is uncertain. Neutrophil homeostasis is maintained by a
fine balance between granulopoiesis, bone marrow storage
and release, intravascular margination, clearance and
destruction. Margination refers to the prolonged transit
of neutrophils through specific organs, which results in
discrete intravascular (marginated) pools; these can be
found within the spleen, liver, bone marrow and, more
controversially, the lung. This review outlines ourCorresponding author: Chilvers, E.R. (erc24@cam.ac.uk).
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Neutrophil production in bone marrow
Neutrophils are produced within haematopoietic cords
interspersed within the venous sinuses of the bonemarrow.
Granulocyte differentiation is regulated by the coordinated
expression of key myeloid transcription factors, with gra-
nulocytes and macrophages differentiating from a common
committed progenitor cell. Transcriptional profiling studies
suggest that macrophages represent the default myeloid
cell, and that granulocytes arise through the selective
expression of a subset of transcription factors (e.g. Egr1,
HoxB7 and STAT3), proteins (e.g. S100A8, S100A9 and
neutrophil elastase) and receptors (e.g. forN-formylmethio-
nyl-leucyl-phenylalanine and granulocyte-macrophage
colony-stimulating factor (GM-CSF)) [1]. Recent data have
indicated for that the small GTPase Rac2 also contributes
to generating the myeloid lineage in haematopoietic
cells [2]. The area of myelopoiesis and the transcription
factors involved has been reviewed extensively elsewhere
[3,4].
The neutrophil population in the bone marrow can be
subdivided into three pools: the stem cell pool, the mitotic
pool and the post-mitotic pool. The stem cell pool consists of
undifferentiated haematopoietic stem cells (HSCs),
whereas the mitotic pool refers to committed granulocytic
progenitor cells that are undergoing proliferation and
differentiation. Finally, fully differentiated mature neu-
trophils make up the post-mitotic pool, which forms the
bone marrow reserve, available for release. Studies that
have used cells labelled with 32P or 3H have shown that, in
humans, the transit time through the post-mitotic pool is
4–6 days [5,6]. Likewise, the bone marrow reserve of
granulocytes in humans has been estimated at 6  1011
cells; given this, and the assumption of a 5-day lag between
DNA labelling of cells in the marrow and their appearance
in blood, the daily turnover of granulocytes through the
blood should be 1.7  109 cells/kg, which accords well with
experimental observations [7–9].
The principal regulator of physiological granulopoiesis
is granulocyte colony stimulating factor (G-CSF) whose
effects include commitment of progenitor cells to the
myeloid lineage [10], proliferation of granulocytic precur-
sors, reduction of transit time through the granulocytic
compartment [11], and release of mature cells from theoi:10.1016/j.it.2010.05.006 Trends in Immunology 31 (2010) 318–324
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receptor, which is a member of the class I cytokine receptor
family. Mice that lack the G-CSF receptor [12,13] and
humans who express a dominant negative receptor
mutation [14,15] are profoundly neutropenic. Interleukin
(IL)-6, GM-CSF and IL-3 also stimulate granulopoiesis in
vivo [16–18], but in all three cases, single knock-out mice
exhibit normal basal levels of granulopoiesis [19–21],
which suggests significant redundancy or reserve. This
conclusion is strengthened by a recent study which has
demonstrated that, although basal granulopoiesis is
impaired in G-CSF and GM-CSF double knockout mice,
IL-6 stimulates increased neutrophil production in
response to lipopolysaccharide (LPS) [22].
Neutrophil release from bone marrow
To exit the bonemarrow,mature neutrophilsmustmigrate
across the sinusoidal endothelium that separates the hae-
matopoietic compartment from the circulation. Neutro-
phils migrate across the bone marrow endothelium
through tight-fitting pores by a unique process of transcel-
lular migration, and pass through the cell body of the
endothelium, rather than at cell–cell junctions [23–25].
Neutrophils maintain G-CSF receptors at high levels on
their surface from early in their development [26]; CXC
chemokine receptor 4 (CXCR4), a G-protein coupled re-
ceptor, is also expressed at low levels on the cell surface of
mature neutrophils. The major ligand for CXCR4 is stro-
mal-derived factor 1 (SDF-1), a CXC chemokine that is
produced constitutively by bone marrow stromal cells. The
interaction between CXCR4 and SDF-1 retains neutro-
phils within the marrow environment, as demonstrated
by the rare autosomal dominant disorder WHIM (warts,
hypogammaglobulinaemia, infection and myelokathesis
[27]). WHIM patients are profoundly neutropenic despite
having increased numbers of neutrophils in the bone mar-
row. These patients have a mutation in CXCR4, which is
proposed to be responsible for impaired neutrophil release
from the bone marrow, by enhancing sensitivity to SDF-1
and promoting retention [28,29]. The role of CXCR4-SDF-1
interaction in regulating neutrophil egress from the bone
marrow is further supported by the finding that Cxcr4
deletion in murine myeloid cells results in increased neu-
trophil release [30], and by the observation that treatment
with a CXCR4 antagonist or blocking antibodies leads to
rapid mobilization of neutrophils from both human and
mouse bone marrow [31–33].
The CXCR4-SDF-1 axis is also important for the reten-
tion of HSCs and as a consequence disruption of CXCR4-
SDF-1 interaction offers the potential to enhance the
mobilization of HSCs for therapeutic harvesting [34,35].
Co-administration of G-CSF with a CXCR4 antagonist
results in synergistic HSC release. One mechanism by
which G-CSF exerts its multiple effects on neutrophil
homeostasis is by inhibiting the CXCR4-SDF-1 axis. Treat-
ment of mice with G-CSF decreases stromal cell SDF-1
production, which correlates with an increase in neutrophil
release [36]; in a further study, G-CSF reduced CXCR4
surface expression specifically on myeloid cells [37]. Exper-
iments in transgenic mice that express various G-CSF
receptor mutations have shown a strong correlation be-tween the magnitude of neutrophil mobilization and the
reduction in SDF-1 protein expression by bone marrow
[38].
The a4 intergrin very late antigen-4 (VLA-4) is
expressed by neutrophils and might mediate their
adhesion to bone marrow stromal cells and endothelium,
which both express the ligand for VLA-4, vascular cell
adhesion molecule-1 (VCAM-1). The possibility of cross-
talk between the CXCR4-SDF-1 axis and the VLA-4-
VCAM-1 interaction has been proposed as important for
the retention and release of neutrophils from the bone
marrow under homeostatic conditions, and furthermore,
signalling through CXCR4 might affect neutrophil release
by modulating the VLA-4-VCAM-1 adhesive interaction
[39]. Expression of VLA-4 is downregulated during neu-
trophil maturation in the bone marrow, and a4 blockade
increases mobilization of neutrophils from the bone mar-
row. Neutralization of CXCR4 and VCAM-1 results in a
significant increase in circulating neutrophils, which
suggests cross-talk between the CXCR4-SDF-1 and VLA-
4-VCAM-1 axes.
Circulating and marginated pools of granulocytes
Almost 50% of 32P-labelled autologous granulocytes
injected into healthy volunteers disappear from the circu-
lation after infusion [40]. However, the number of neutro-
phils that remain in the circulation can be increased by the
addition of adrenaline to the infusion bag [41]. It is there-
fore considered that a proportion of the granulocytes that
exit the circulation could be mobilized back into this freely
circulating pool; this recoverable portion of granulocytes is
termed themarginated pool. It has been estimated that the
total blood granulocyte pool is 65  107 cells/kg, with 49%
of cells residing in the circulating pool and the remaining
51% in the marginated pool [7]. Prednisolone increases the
size of both the circulating and marginated pools, while
exercise and adrenaline cause a shift of cells from the
marginated to the circulating pool. Bacterial endotoxin
increases the size of both the total blood granulocyte pool
by increasing bone marrow release, as well as the pro-
portion of cells within the marginated pool. These pioneer-
ing studies have underpinned the modern concept of
circulating and marginated intravascular granulocyte
pools (Figure 1).
The marginated neutrophil pool
The size of an individual marginated pool is the product of
themean intravascular transit time through the organ (i.e.
the mean time taken for neutrophils to pass through the
capillary bed) and its blood flow. Using radiolabelled neu-
trophils and a range of analytical techniques, mean neu-
trophil intravascular transit time has been measured for
the liver (2 min [42]), spleen (10 min [42]) and bone
marrow (10 min [43]).
The size of the pulmonary marginated granulocyte pool
is more controversial. A large body of data suggest that the
lung is the predominant site of physiological neutrophil
margination [44], but this has been called into question by
data obtained using leukocyte scintigraphy, which demon-
strate that the lungs of healthy humans are only modestly
engaged in physiological neutrophil pooling [45]. The lungs319
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Figure 1. Factors that affect the size of the marginated and circulating granulocyte
pools.
G-CSF is the principal regulator of granulopoiesis and affects the commitment of
progenitor cells to the myeloid lineage, proliferation of granulocytic precursors, as
well as reducing transit time through the granulocyte compartment and
stimulating the release of mature cells from the bone marrow. Neutrophil
release from the bone marrow into the total blood granulocyte pool reflects loss
of interaction between CXCR4 and SDF-1, and between VLA-4 and VCAM-1.
Neutrophils within the total blood pool then enter either the marginated or freely
circulating granulocyte pool that are of similar size in humans. A number of factors
including exercise, drugs and infection affect the relative size of these two pools,
as indicated.
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Figure 2. Physiological fate of granulocytes within the blood pool. The absence of
infection or injury (which results in the targeted migration of neutrophils into the
inflamed tissues), neutrophils exit the total blood granulocyte pool and can be
found in the liver, spleen and bone marrow in approximately equal proportions.
Neutrophil apoptosis within these tissues results in macrophage recognition and
ingestion that leads to G-CSF generation, which in turn stimulates granulopoiesis.
Neutrophils within inflamed tissue undergo apoptotic or necrotic cell death or are
lost to the body following trans-epithelial migration.
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pulmonary granulocyte pool is determined predominantly
by the mean pulmonary transit time. There has been little
consensus regarding this variable, and a plethora of exper-
imental methodologies have been applied in attempts to
produce definitive results, with limited success (reviewed
previously [45]).
The biodistribution of neutrophils is also determined by
their maturation and activation status; this might be
relevant to the controversy outlined above, because tech-
niques used to purify neutrophils for such studies might
inadvertently activate them. This is highlighted by leuko-
cyte scintigraphy in subjects injected with granulocytes
purified with Percoll-saline density gradients and labelled
with 111In, which show marked retention in the lungs and
slow accumulation in the liver and spleen [45]. Mature
peripheral blood neutrophils have been shown to localize to
the liver, bone marrow and, to a lesser extent, the spleen;
younger marrow-derived cells home back mainly to the
bone marrow, while inflammatory peritoneal neutrophils
localize predominantly to the liver, but also to the lungs
[46]. These latter post-migratory neutrophils are highly
activated and their biodistribution might be non-physio-
logical. However, this might help to predict the behaviour
of circulating neutrophils in systemic inflammatory dis-
ease.
Neutrophil uptake and removal by the liver, spleen and
bone marrow
After injection into healthy individuals, neutrophils leave
the vascular compartment with a time course that declines
exponentially and a half life of about 7 h, and undergo320destruction in the reticuloendothelial system [47]. The
mechanisms of physiological neutrophil destruction in vivo
are poorly defined.
We and others [48–50] have identified in the mouse a
senescent neutrophil phenotype that has increased surface
expression of CXCR4, which develops just before apoptosis.
It is proposed that under physiological conditions, upre-
gulation of CXCR4 on circulating neutrophils supports
homing to the bone marrow, where these cells undergo
apoptosis and are phagocytosed by stromal macrophages.
This in turn stimulates G-CSF production, which provides
the required homeostatic link between clearance and pro-
duction/release (Figure 2). Homing of senescent neutro-
phils to the bone marrow is inhibited by pertussis toxin,
which supports a role for a G-protein receptor such as
CXCR4 in this process [45]. This model implies a dual role
for CXCR4 in neutrophil homeostasis, where it both
retains neutrophils in the marrow until they reach matur-
ity, and acts as a signal to home senescent cells to the
marrow for destruction. The relevance of this signalling
pathway in humans is uncertain.
Cxcr4 deletion is embryonically lethal [51], however,
data from a myeloid-specific Cxcr4 mouse knockout
suggest that CXCR4 is not the only regulator of neutrophil
clearance from the circulation [52]. Mice that lack myeloid
CXCR4 exhibit circulating neutrophilia, with premature
release of neutrophils from the bone marrow. Adoptive
transfer of knockout cells to wild type animals has demon-
strated decreased homing to the bone marrow, which is
consistent with previous findings [49]. However, neutro-
phils that lack CXCR4 have a circulating half life that is
not significantly different from that of wild type cells; this
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senescent neutrophils to the bone marrow, other (as yet
unidentified) factors and/or mechanisms are also import-
ant in regulating this process. This resonates with the
observations that neutrophil disappearance from the blood
(unlike erythrocyte loss) follows a time course that fits to a
mono-exponential curve, which is a pattern that is not
consistent with exclusively senescence-based destruction.
A role for the liver in regulating circulating neutrophil
numbers has also been proposed. The liver is thought to
offer a clearance pathway in which neutrophil phagocyto-
sis is undertaken by hepatic Kupffer cells after P-selectin-
mediated hepatic sequestration [53]. Selective upregula-
tion of P-selectin in response to low-dose LPS has been
found within the liver (but not the lungs or spleen), and
phagocytosis of circulating apoptotic neutrophils is almost
exclusively limited to the liver, with cells being phagocy-
tosed by Kupffer cells through surface phosphatidylserine
interactions.
Effects of systemic stress and inflammation on
neutrophil kinetics
Stress and systemic inflammation are associated with
circulating neutrophilia and multiple inflammatory
mediators including leukotriene B4, complement com-
ponent C5a, IL-8 and tumour necrosis factor-a (TNFa)
have been shown to induce neutrophilia when injected into
experimental animals. It has been suggested that mobil-
ization of neutrophils from a marginated pool within the
bone marrow sinusoids explains this increase [54]. How-
ever, more recent data have suggested that cells are mobi-
lized from the haematopoietic compartment in response to
concentration gradients across the sinus wall of bone
marrow sinusoids, which are generated by the production
of mediators such as macrophage inflammatory protein-2,
G-CSF and CXCL1 (KC) at inflammatory sites [25]. The
precise mechanism by which inflammation leads to circu-
lating neutrophilia is incompletely understood. However,
acute mobilization of neutrophils from the bone marrow
might require the coordinated, yet distinct, actions of
G-CSF and CXC chemokines, with G-CSF disrupting the
CXCR4-SDF-1 retention mechanism and CXC chemokines
stimulating neutrophil chemotaxis across the bonemarrow
endothelium [55].
A role for SDF-1 in attracting a second influx of neu-
trophils into the lungs in acute lung injury has also been
suggested [56]. SDF-1 expression (both protein andmRNA)
has been found to be increased in the pulmonary epi-
thelium in patients with histologically proven acute lung
injury and mice with LPS-induced pneumonitis. Addition-
ally, upregulation of CXCR4 expression has been noted on
the cell surface of the neutrophils that have migrated into
the lung, and neutrophil migration is ameliorated by the
use of an SDF-1 blocking antibody.
The histotoxic potential of neutrophils dictates the need
for effective processes to prevent inappropriate tissue-
specific accumulation and activation. The key mechanism
for this is priming, which dictates that neutrophil acti-
vation is a two-step process that requires an initial
exposure to mediators such as cytokines. These factors
can be divided into early-phase cytokines such as TNFa,IL-1b, and pathogen associated molecular patterns
(PAMPs) such as endotoxin, or late-phase chemoattrac-
tants and growth factors including IL-8, LTB4 and GM-
CSF. Priming can also be induced by the interaction of
neutrophils with activated endothelial surfaces (previously
reviewed [57]). Maximal neutrophil degranulation and
activation of the NADPH oxidase occurs only in cells that
have been primed before activation [58]. Crucially, priming
is also an absolute requirement for neutrophil-mediated
tissue injury, and affects neutrophil cytoskeletal organiz-
ation to induce shape change and reduce deformability
[59]; this causes stiffening of the neutrophils, which makes
themmore prone to retention in capillary beds. Neutrophil
priming, including shape change, has been shown to be
reversible in vitro [60], however, there are limited data
about the effects of priming on neutrophil kinetics in vivo.
Up to 15% of the cardiac output can pass through an
inflamed site (as observed in patients with active inflam-
matory bowel disease), therefore, all neutrophils are
expected to be exposed to the priming stimulus within
minutes. However, in vivo studies in inflammatory dis-
orders have found a maximum of 60% of circulating neu-
trophils in a primed state [61,62]. Assuming that all
neutrophils that emerge from an inflammatory site are
primed, and that the life span of a primed neutrophil is no
shorter than an unprimed one (6–8 h), de-priming seems
mathematically justified. For example, during inflam-
mation, the rate of priming is equal to the sum of the rate
of de-priming and the rate of destruction; consequently, if
no de-priming occurs, such studies should demonstrate
that at least 97% of circulating neutrophils are in the
primed state, but this has not been the case, suggesting
that de-priming might occur in vivo. The lungs receive the
entire cardiac output, and thus have the potential to
protect the systemic circulation, therefore, they offer a
possible site of neutrophil de-priming where primed cells
are retained until they de-prime and can be returned to the
systemic circulation in a safe, quiescent state (Figure 3).
If the lungs afford a site for physiological neutrophil de-
priming, it should be possible to measure a gradient of
primed cells across the pulmonary vascular bed. The trans-
pulmonary gradient of H2O2 production (a marker of prim-
ing/activation status) by zymosan-activated neutrophils
has been examined in septic patients without lung infil-
trates, in patients with lung injury, and control patients
who are undergoing elective surgery [63]. Septic patients
have higher H2O2 in mixed venous blood (blood yet to enter
the pulmonary circulation) compared with arterial blood
(blood that has left the pulmonary circulation), which is
consistent with the idea that neutrophils primed in the
periphery are sequestered and de-primed within the lungs.
Patients with lung injury, however, have higher levels of
H2O2 in arterial blood, which suggests that the de-priming
mechanism fails and the lungs themselves become a site of
neutrophil priming. Control patients have no measurable
gradient of H2O2 production between venous and arterial
blood samples. Further evidence from an animal model
also implicates the lung as a potential site of in vivo de-
priming. In rats, neutrophil priming has been compared
between blood entering and exiting the lungs [64]; 4 h after
experimentally generated pneumonia, a higher proportion321
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Figure 3. Effects of local and systemic inflammation on neutrophil kinetics. Tissue inflammation results in the release of multiple inflammatory mediators and subsequent
neutrophil priming. Priming results in a marked change in neutrophil shape and rheology that leads to retention within the capillary microvascular bed of the lung. The liver
is thought to play a particularly important role in recognizing and removing damaged neutrophils. Circulating inflammatory markers stimulate granulopoiesis and rapid
release of preformed mature neutrophils from the bone marrow.
Review Trends in Immunology Vol.31 No.8of primed neutrophils enter the lungs than leave, as quan-
tified by the presence of F-actin rims that are visible within
primed cells. This demonstrates that the lungs do seques-
ter primed neutrophils and therefore might protect the
systemic circulation from the potentially damaging effects
of primed cells.
Conclusions
The crucial role of neutrophils in innate immunity, coupled
with their proclivity to cause tissue injury, mandate that
their formation, mobilization and clearance are tightly
controlled. G-CSF regulates myelopoiesis, while the cyto-
kine responsive CXCR4-SDF-1 signalling axis acts as the
principal regulator of bone marrow neutrophil retention/
release. The factors that are responsible for the removal of
neutrophils from the circulation are unclear, but upregula-
tion of CXCR4might contribute to homing of neutrophils to
the bonemarrow for disposal. The lungs are now thought to
play little part in physiological neutrophil sequestration,
but could have an important protective role by filtering
primed neutrophils from the circulation and thus facilitat-
ing de-priming. The potentially protective role of the lungs,
and whether this is a passive or active process, requires
further investigation, but it could lead to novel therapeutic
strategies for inflammatory conditions. Further work is
also required on the potential of PAMPS and Damage-
associatedmolecular patternmolecules (DAMPs) to induce
neutrophil priming and modulate neutrophil kinetics.
Although we have gained new insights into the mechan-
isms of neutrophil release from the bone marrow, the
molecular mechanisms that regulate their re-uptake in
the liver, spleen and bone marrow are less certain and
warrant further investigation.322Acknowledgements
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